GH Research PLC, also known as GHRS, is a highly reputed and internationally recognized pharmaceutical company. Headquartered in Dublin, Ireland, the company is renowned in the field of medical research, primarily focused on the development and discovery of advance therapies for the treatment of various ailments.
GH Research PLC was established with the prime motive to explore, create, and cultivate innovative and cost-effective therapies that significantly enhance the quality of human life. Their commitment to bettering human health shows in the game-changing solutions they provide to the healthcare sector.
The company is a market leader, known for its robust research and development capabilities. GH Research PLC's R&D department works tirelessly, leveraging state-of-the-art technology and extensive medical knowledge to develop breakthrough medications and therapies. They coordinate closely with a vast network of medical practitioners, hospitals, and research institutes around the globe to stay updated with the latest advancements and incorporate them into their research processes.
In their quest to become one of the leading pharmaceutical organizations globally, GHRS has made significant contributions to the pharmaceutical world, particularly in therapies related to neurological disorders. One of the company's flagship projects is the development of GH001 and GH002 - inhalation and intravenous solutions respectively, which are at various stages of clinical trials for the treatment of cluster headache, a debilitating condition affecting millions of people worldwide.
Through their rigorous work, GHRS aims to address unmet therapeutic needs and is dedicated to the prolonged fight against chronic illnesses and life-threatening diseases. Recognized for its dedication to medical progress, the company has created partnerships and alliances with various healthcare organizations and stakeholders. Together, they contribute to bringing healthcare solutions, innovations, and scientific advancements to life.
GHRS is run by a proficient and experienced management team, which plays a pivotal role in driving the company towards achieving its strategic objectives and vision, including innovation, affordability, and accessibility of medications for all.
With a strong ethical approach to doing business and commitment to Corporate Social Responsibility, GH Research PLC is strengthening its strides in the pharmaceutical world. They prioritize maintaining goodwill and understanding with all their stakeholders and adopt a transparent approach in all professional interactions.
With every effort and initiative, GHRS seeks to cultivate and strengthen its position as a leading pharmaceutical entity. This company's persistent dedication to innovation and exceptional R&D capabilities aims to redefine human health's future landscapes. It remains a recognizable force in the pharmaceutical sector, backed by their unwavering determination to better the lives of patients, healthcare professionals, and the global community alike.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
GH Research PLC (NASDAQ: GHRS) has filed its September 2026 foreign private issuer report under the Securities Exchange Act of 1934. The report was officially signed by Company Secretary Magnus Halle on September 11, 2026, confirming the reporting period and Halle's authorization as a company representative. This filing was submitted to the U.S. Securities and Exchange Commission.
GH Research (GHRS) reported widening net losses of US$15.15 million for Q2 and US$34.11 million for the first six months of 2026, intensifying focus on the company's spending and clinical milestones. The company's investment narrative heavily relies on the success of its GH001 program for depression, with ongoing cash burn raising concerns about future dilution for shareholders. While the clinical timeline remains intact, the financial results underscore the importance of efficient trial execution and favorable future funding.
Zacks Research has upgraded GH Research (NASDAQ:GHRS) from a "strong sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with a $45.00 price target. The clinical-stage biotechnology company, which focuses on psychedelic-inspired treatments for neuropsychiatric disorders, saw its shares rise 4.6% to $29.49, near its 52-week high. GH Research also reported a narrower-than-expected quarterly loss of $0.23 per share, beating the consensus estimate of a $0.29 loss.
GH Research PLC (NASDAQ:GHRS) has received an average rating of "Moderate Buy" from analysts, with ten out of twelve recommending a buy and an average 12-month price target of $45.00 against a current price of $28.19. Despite beating quarterly earnings estimates, analysts foresee continued losses for the company in the coming years. Institutional investors show strong interest, holding 56.9% of the company's stock.
This article provides an AI-driven analysis for Gh Research Plc (NASDAQ: GHRS), highlighting strong sentiment across all horizons and identifying an exceptional risk-reward short setup. It details three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide traders. The analysis emphasizes technical indicators and risk management for potential moves in the stock.